Adjuvant chemotherapy with doxorubicin-containing regimen for 326 stage II breast cancers: 15-year results

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 3, 1997, Pages 219-225

  Ferrière, Jean Pierre ^a   Charrier, Sabine ^a   Curé, Hervé ^a   Kwiatkowski, Fabrice ^a   Courtadon, Michel ^a   Bélembaogo, Ernest ^a   De Latour, Monique ^a   Achard, Jean Louis ^a   Dauplat, Jacques ^a   Chollet, Philippe ^a  

^a CENTRE JEAN PERRIN   (France)

Author keywords

Adjuvant chemotherapy; Breast cancer; Cardiac effects; Doxorubicin; Survival

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; TAMOXIFEN; VINCRISTINE;

ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MASTECTOMY; MENOPAUSE; NEUTROPENIA; PERICARDITIS; SKIN NECROSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HEART DISEASES; HUMANS; MASTECTOMY, MODIFIED RADICAL; MENOPAUSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0343924286     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199706000-00001     Document Type: Article

References (21)

1. Bonadonna G, Valagussa P. The contribution of medicine to primary treatment of breast cancer. Cancer Res 1988;48:2314-24.
2. Fisher B, Fisher ER, Redmond C, et al. Ten years results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol 1986;4:929-41.
3. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 37,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15, 71.
4. Henderson C. Clinical decision-making in the use of adjuvant systemic therapy. ASCO Educational Book, 30th Annual Meeting, Dallas, Texas (USA), May 14-17, 1994, p. 6.
5. Misset JL, di Palma M, Delgado M, Plagne R, Chollet P, Fumoleau P, et al. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol 1996;14:1136-45.
6. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957;11:359.
7. Le Doussat V, Tubiana-Hulin M, Friedman S, et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer 1989;64:1914-21.
8. McGuire WL, De La Garza M, Chamness GC. Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 1977;37:637-9.
9. Tancini G, Bonadonna G, Valagussa P, et al. Adjuvant CMF in breast cancer: Comparative 5 years results of 12 versus 6 cycles. J Clin Oncol 1983;1:2-10.
10. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;11: 1281-8.
11. Kaplan EL, Meier P. Non parametric estimation from observations. Journal of the American Statistical Association 1958;53:457-81.
12. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22(4):719-48.
13. Cox DR. Regression models and life tables. J R Stat Soc B 1972, 34:187-202.
14. Buzdar A, Hortobagyi G, Smith T, et al. Ten year results of FAC adjuvant chemotherapy trial in operable breast cancer. Proc Am Soc Clin Oncol 1987;6:63.
15. Fisher B, Redmond C, Laurence Wickerham D, et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the national surgical adjuvant breast and bowel project experience. J Clin Oncol 1989;7(5):572-82.
16. Beuzedoc P, Mosseri V, Dorval T. Adriamycin-based combination chemotherapy significantly improves overall survival in high risk premenopausal breast cancer patients. [Abst. 55P.] Proceedings of the 4th International Conference on Adjuvant Therapy of Primary Breast Cancer, 1992:72.
17. Buzzoni R, Bonadonna G, Valagussa P. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991;9:2134-40.
18. Buzdar A., Hortobagyi G, Kan S, et al. Cancer adjuvant therapy trials of M. D. Anderson Cancer Center. Results of four prospective studies. Proceedings of the 7th International Conference on the Adjuvant Therapy of Cancer, 1993:38.
19. Budman DR, Wood W, Henderson IC. Initially findings of CALCGB 8541: a dose intensity trial of cyclophosphamide (C), doxorubicin (A) and fluorouracil (F) as adjuvant treatment of stage II, node positive female breast cancer. [Abstr 29] Proc Am Soc Clin Oncol 1992;11:51.
20. McGuire WL. Prognostic factors for recurrence and survival in human breast cancer. (9th San Antonio Breast Cancer Symposium: Plenary lecture). Breast Cancer Res Treat 1987;10:5-9.
21. Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M. D. Anderson Hospital and Tumor Institute. NCI Monogr 1986;1:105-9.